[Dual-chamber implantable automatic defibrillators. Experiences apropos of 16 cases].
In view of the large number of inappropriate shocks observed in patients with implanted defibrillators, improved detection of ventricular arrhythmias has become a major objective. The addition of an atrial catheter has been proposed to improve discrimination between ventricular and non-ventricular arrhythmias. Besides this function, the additional catheter could be used for DDD pacing without risk of interaction between the pacemaker and defibrillator. The authors report their initial experience in 16 patients implanted with a DDD pacemaker. The indication was resuscitated sudden death (N = 5) or ventricular tachycardia (N = 11). The choice of a DDD defibrillator was justified by a bradycardia (N = 9), haemodynamic factors (N = 4) or supraventricular tachycardia (N = 3). The devices used were the Defender 9001 (ELA Medical SA, France, N = 3), the Ventak AV 1810 and the Ventak AV II DR 1821 (Guidant/CPI, Inc. USA, N = 11 and N = 2 respectively). There were three immediate complications. After 2 to 29 months' follow-up, 5 patients had received appropriate treatment by their devices. Five patients had inappropriate shocks : one patient received a shock triggered by electrical interference, two others had no active sensing algorithme when the shocks were delivered, and the other two had an activated algorithme with 1/1 conduction of a supraventricular arrhythmia. No recurrences were recorded after reprogramming the device. DDD or VDD pacing was permanent in 9 patients and intermittent in 3 others. Seven patients had dilated cardiomyopathy and severe cardiac failure and were clinically improved by dual chamber pacing. In many patients, candidates for a defibrillator, this new generation of devices has improved specificity of arrhythmia detection and cardiac pacing without risk of interaction. The authors propose a classification of the indications for a DDD defibrillator.
Le Franc
P
P
Service de cardiologie A, Hôpital cardiologique, Lille.
Klug
D
D
Lacroix
D
D
Kouakam
C
C
Jarwé
M
M
Kacet
S
S
D000465:Algorithms; D001145:Arrhythmias, Cardiac / Q000175:diagnosis / Q000628:therapy; D001919:Bradycardia / Q000628:therapy; D002304:Cardiac Pacing, Artificial / Q000379:methods; D002311:Cardiomyopathy, Dilated / Q000628:therapy; D002404:Catheterization / Q000295:instrumentation; D017147:Defibrillators, Implantable / Q000009:adverse effects / Q000145:classification; D004867:Equipment Design; D004868:Equipment Failure; D005260:Female; D005500:Follow-Up Studies; D006323:Heart Arrest / Q000517:prevention & control / Q000628:therapy; D006325:Heart Atria; D006333:Heart Failure / Q000628:therapy; D006352:Heart Ventricles / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial; D012151:Resuscitation; D013617:Tachycardia, Supraventricular / Q000628:therapy; D017180:Tachycardia, Ventricular / Q000628:therapy